TrialBlood advances2026

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.

Shebli Atrash et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.